Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ADAPY Relative to the S&P 500

ADAPY Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Adaptimmune Therapeutics plc (OTCMKT:ADAPY) seasonal charts above shows that a Buy Date of December 17 and a Sell Date of May 3 has resulted in a geometric average return of 27.98% above the benchmark rate of the S&P 500 Total Return Index over the past 9 years. This seasonal timeframe has shown positive results compared to the benchmark in 7 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 9 years by an average of 66.05% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 9 years of data is available for shares of ADAPY, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

To download ADAPY seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ADAPY